PRVA

Privia Health Group, Inc. (PRVA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Privia Health Group, Inc. is a technology-driven, national physician-enablement company operating in 16 markets across the United States. The company organizes physicians into Medical Groups to achieve better outcomes, lower costs, and improved patient experiences through a unique practice model combining partnership advantages with provider autonomy.

Key Financial Metrics

Liquidity: The company holds $419.5 million in cash and cash equivalents. It maintains a $125 million revolving credit facility (amended to $250 million in May 2026) with no outstanding borrowings as of March 31, 2026.

Margins: Operating margin was 1.2% for Q1 2026 compared to 1.1% in Q1 2025. Adjusted EBITDA margin improved to 28.5% from 25.6% year-over-year.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 25.8% to $603.8 million, driven by a 25.5% increase in Fee-for-Service (FFS) patient care revenue and a 56.5% surge in shared savings revenue.
• Profitability Decline: Despite revenue growth, Net Income attributable to Privia decreased 27.4% to $3.1 million. This was primarily due to a significant increase in the provision for income taxes (effective tax rate rose to 60.2% from 25.8%) driven by unfavorable tax impacts from equity award vesting and Section 162(m) limitations.
• Expense Increases: Provider expenses rose 26.8% to $475.1 million, and General and Administrative expenses increased 30.7% to $41.5 million, largely due to higher salaries, benefits, and stock-based compensation.
• Cash Flow: Net cash used in operating activities increased to $49.5 million (from $24.1 million used in Q1 2025), primarily due to a $112.8 million increase in accounts receivable.

Guidance, Outlook, and Risks

Management Commentary: Management highlights strong organic growth in Implemented Providers (up 13.6% to 5,535) and Attributed Lives (up 26.5% to 1.6 million). The company continues to invest in sales, marketing, and technology to support its transition to Value-Based Care (VBC). No specific forward-looking financial guidance was provided in this text.

Subsequent Event: On May 6, 2026, the company amended its Revolving Credit Agreement to increase capacity to $250 million and extend the term to 2031.

Risks and Contingencies:

• Regulatory Risk: Heavy reliance on government healthcare programs (Medicare/Medicaid) and compliance with complex laws like HIPAA.
• Concentration Risk: Three payers accounted for 62% of total revenue and 82% of accounts receivable.
• Operational Risk: Dependence on relationships with Medical Groups (some non-owned) and the athenahealth EMR vendor.
• Legal: Ongoing ordinary course legal proceedings, including medical malpractice claims, though none are expected to be materially adverse.

Investor Verification Checklist

• Tax Provision Volatility: Verify the sustainability of the 60.2% effective tax rate and the specific impact of equity vesting events on future quarters.
• Accounts Receivable Growth: Assess the $112.8 million increase in receivables and its impact on working capital and cash conversion cycles.
• Payer Concentration: Review the stability of contracts with the top three payers representing the majority of revenue and receivables.
• Non-GAAP Reconciliations: Scrutinize the adjustments made to reach Adjusted EBITDA, particularly the $4.1 million in "other expenses" and stock-based compensation.
• Debt Facility Utilization: Monitor the utilization of the newly expanded $250 million credit facility following the May 2026 amendment.